Aaron Cowen, Director, 10% Owner at Benitec Biopharma Inc. (BNTC), bought 155,810 shares at $12.85 ($2.1M) on 2025-12-23, disclosed to the SEC on 2025-12-29.
Open-market purchase of $2.1M BNTC by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.85 | 7,400 | $95K | 4.6% |
| 2 | $12.85 | 42,600 | $547K | 26.6% |
| 3 | $13.10 | 2,516 | $33K | 1.6% |
| 4 | $13.10 | 14,320 | $188K | 9.1% |
| 5 | $13.44 | 11,587 | $156K | 7.6% |
| 6 | $13.44 | 11,587 |
| $156K |
| 7.6% |
| 7 | $13.44 | 65,800 | $884K | 43.0% |
| Total | $13.21 avg | 155,810 | $2.1M | 100% |
| Filing → |
| PROK | BUY | 2022-09-08 | $49K | — | Filing → |
| PROK | BUY | 2022-09-01 | $34K | — | Filing → |